Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

Published:2014-01 Issue:1 Volume:38 Page:10-20
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Soverini Simona,Branford Susan,Nicolini Franck E.,Talpaz Moshe,Deininger Michael W.N.,Martinelli Giovanni,Müller Martin C.,Radich Jerald P.,Shah Neil P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference79 articles.

1. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia;de Klein;Nature,1982

2. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22;Groffen;Cell,1984

3. NCCN Clinical Practice Guidelines in Oncology. NCCN Chronic Myelogenous Leukemia Guidelines Vers 4;NCCN,2013

4. Gleevec (imatinib mesylate) prescribing information,2013

5. Sprycel (dasatinib) prescribing information,2013

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S-nitrosoglutathione (GSNO) induces necroptotic cell death in K562 cells: Involvement of p73, TSC2 and SIRT1;Cellular Signalling;2024-12

2. A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations;The Journal of Applied Laboratory Medicine;2024-09-03

3. Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB‐positive acute lymphoblastic leukemia patients: A retrospective multicenter study;Cancer;2024-08-13

4. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

5. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results;Leukemia;2024-05-16